

Index

- A**
- Abatacept, 67
 - Absolute fracture risk model (FRAX), 242
 - Acetaminophen, 62, 75
 - aCL ELISA tests, 233
 - Acupuncture, 54
 - Acute gouty arthritis therapy, 209
 - Acute pseudogout precipitators, elderly, 216
 - Aerobic exercise, 109, 125, 126, 128, 261
 - AION, 226
 - Alcoholic myopathy, 270
 - Amyloid myopathy, 269–270
 - Anakinra, 67
 - Analgesics, 52–53
 - ANCA-associated renal vasculitis
 - age indicator, 202
 - cyclophosphamide dose, 202
 - diagnosis, 32
 - morbidity and mortality determinant, 201
 - therapy, 32
 - Angiotensin converting enzyme (ACE), 262
 - Ankylosing Spondylitis (AS), 109–110
 - atherosclerosis, 20–21
 - clinical features, 104
 - inspiratory muscle training, 110
 - pathology, 110
 - physical therapy interventions, 104
 - sacroilitis, 110
 - self-management, 110
 - Anticonvulsants, 52
 - Antidepressants, 51–52
 - Antimalarials
 - clinical pharmacology, 154
 - efficacy, 154–155
 - safety, 155
 - Antineutrophil cytoplasmic antibodies, 198
 - Antiphospholipid (aPL) antibodies
 - diseases, 233–234
 - elderly, 234–236
 - Antiphospholipid syndrome (APS)
 - aCL antibodies, prevalence
 - aCL ELISA tests, 233
 - Louisville reference standards, 233
 - venous thromboembolism, 233
 - aPL antibodies, prevalence
 - autoimmune diseases, 233
 - elderly, 234–236
 - non-parametric tests, 233
 - SLE patients, 233
 - transient ischemic attacks and strokes, 233
 - variability, 233
 - classification criteria
 - clinical, 232
 - laboratory, 232
 - clinical and subclinical atherosclerosis, 20
 - features, 231
 - morbidity and mortality, 232–233
 - Anti-TNF agents
 - adalimumab, 164
 - efficacy, 164
 - etanercept, 164
 - infliximab, 165
 - safety, 164
 - Anti-TNF alpha agents, 66–67
 - Anti-TNF α (alpha) therapy, 37
 - Apoptosis, 4
 - APS. *See* Antiphospholipid syndrome (APS)
 - Arthritis-specific federal policy initiatives
 - CDC Arthritis Program, 97
 - Healthy People 2010, 96
 - The National Arthritis Action Plan, 96–97
 - National Arthritis Act of 1974, 95–96
 - National Arthritis Plan of 1976, 95–96
 - National Institute of Arthritis, 96
 - Arthrocentesis
 - corticosteroids, 113–114
 - elbow
 - joint effusion, 118
 - olecranon bursa injection, 118
 - tennis elbow injection, 118
 - foot
 - ankle injection (tibio-talar), 121
 - metatarsophalangeal joint injection, 122
 - Morton’s neuroma, 122
 - plantar fasciitis injection, 121
 - posterior tibialis tendon sheath injection, 121–122
 - hip, 120
 - hyaluronates, 114
 - indications, 113
 - knee injection, 120–121
 - local anesthetics, 114
 - post injection care, 116
 - precautions and contraindications, 115
 - shoulder
 - acromioclavicular joint (ACJ) injection, 117
 - biceps tendon injection, 117–118
 - glenohumeral joint injection, 116
 - subacromial-subdeltoid (SA-AD) bursal injection, 116–117
 - suprascapular nerve block, 117
 - side effects and complications, 114–115

- Arthrocentesis (*cont.*)
 technical considerations, 115–116
 wrist and hand
 carpal tunnel injection, 118–119
 De Quervain's tenosynovitis injection, 120
 first carpometacarpal (CMC) joint, 119
 ganglion, 119
 metcarpophalangeal and proximal interphalangeal joints injection, 119
 trigger finger injection, 119–120
- Arthroplasty, 82
- Atherosclerosis
 ankylosing spondylitis, 20–21
 antiphospholipid syndrome (APS), 20
 ASCVD, epidemiology of, 19–20
 atheroma, 17
 clinical implications, preventive strategies
 antimalarial agents, 22
 biological therapies, 22
 corticosteroids, 21
 methotrexate, 22
 mycophenolate mofetil, 22
 NSAIDs and COX-2 inhibitors, 21
 statins, 21–22
 pathologic mechanisms, SLE and RA, 18–19
 primary systemic vasculitis, 21
 psoriasis and psoriatic arthritis, 20
 shared disease mechanisms, 17–18
 systemic sclerosis, 21
- Atherosclerotic cardiovascular disease (ASCVD)
 endothelial dysfunction, 18
 epidemiology
 RA and ASCVD mortality, 19
 SLE and ASCVD mortality, 19
 subclinical atherosclerosis in SLE and RA, 19–20
 pathologic mechanisms, 18–19
- Autoimmunity, 290
- Azathioprine, 66
- B**
- Barthels Index, 88
- Basic calcium phosphate (BCP) diseases
 and CPPD pathogenesis, 219–220
 Milwaukee shoulder syndrome, 219
- B cells, 6
- Biologic response modifiers (BRMs), 159–167
 abatacept, 166
 anakinra, 166–167
 cancer, older RA patient, 163–164
 other safety concerns, 164
 rituximab, 167
 TNF- α action, 159
 TNF inhibiting agents, older RA patient, 163
- Biomechanic factors
 knee laxity, 180
 LLI, 180–181
 proprioception, 181
- Bisphosphonate therapy
 males, 242
 osteonecrosis of jaw, 244
- BMD. *See* Bone mineral density (BMD)
- Bone
 age-related changes
 cytokines, 12
 GH-IGF axis, 12
 vitamin D, 14–15
 anatomy and physiology, 11
 fracture healing, 12–13
 remodeling, 241
 resorption, 241
 senile osteoporosis, 11–12
- Bone mineral density (BMD), 179
- Bone remodeling, 241
- Bone resorption, 241
- Boost test, 39
- Bracing or splinting, 77
- BRMs. *See* Biologic response modifiers (BRMs)
- C**
- Calcium-containing crystal-associated arthropathies. *See* Calcium pyrophosphate dihydrate (CPPD) deposition disease
- Calcium pyrophosphate dihydrate (CPPD)
 deposition disease
 and BCP pathogenesis, 218–219
 clinical spectrum, 214–215
 diagnosis
 characteristic rhomboid shape demonstration, 216
 MSKUS, 216–217
 epidemiology, 213
 osteoarthritis and, 215
 treatment
 acute pseudogout attack management, 217
 biologic therapy, 218
 colchicine or corticosteroids, 218
 dietary calcium, 218
 hydroxychloroquine or methotrexate, 218
 magnesium, 218
 NSAIDs, 217
 probenecid, 218
- Cataracts, medium- and small-vessel vasculitis, 203–204
- Cevimeline, 290
- Chloroquine, 66
- Churg-Strauss syndrome (CSS), 200
- CNS angiitis
 diagnosis, 32–33
 therapy, 33
- Cognitive-behavioral therapy (CBT), 53
- Colchicine, 209, 270
- Comorbid psychiatric disorders, 53
- Complementary and alternative medicine (CAM) practices, 77
- Corticosteroids, 21, 270
- CPPD. *See* Calcium pyrophosphate dihydrate (CPPD) deposition disease
- Cryotherapy, 76
- Crystal arthropathies, 179
- Crystal induced inflammation, 220
- Cyclooxygenase-2 (COX-2) inhibitors, 21
- Cyclophosphamide, 282, 290
- Cyclosporin, 66, 289–290
- D**
- Degenerative lumbar spinal stenosis (LSS)
 classification, 102
 definition, 102
 pathophysiology, 103
 physical examination findings and interventions
 Maine lumbar spine study, 105
 sensory and proprioceptive changes, 102
 therapeutic exercise, 104–105
- Dendritic cells (DC), 6
- Depot corticosteroid crystals, 221

- Dermatomyositis (DM)
 autoantibodies, 265, 266
 diagnosis, 265
 incidence rates, 265
 malignancy, 266–267
- Deyo-Charlson Comorbidity Index, 211
- Disease-modifying anti-rheumatic drug (DMARD)
 antimalarials
 clinical pharmacology, 154
 efficacy, 154–155
 safety, 155
 anti-TNF agents
 adalimumab, 164
 efficacy, 164
 etanercept, 164
 infliximab, 165
 safety, 164
 biologic response modifiers
 abatacept, 166
 anakinra, 166–167
 cancer, older RA patient, 163–164
 other safety concerns, 164
 rituximab, 167
 TNF- α (alpha) action, 159
 TNF inhibiting agents, older RA patient, 163
 introduction, 151–152
 leflunomide
 clinical pharmacology, 155
 efficacy, 156
 safety, 156
 methotrexate
 clinical pharmacology, 156–157
 efficacy, 157
 safety, 157–158
 physiologic changes with aging
 pharmacodynamics, 153–154
 pharmacokinetics, 152–153
 sulfasalazine
 clinical pharmacology, 158
 efficacy, 158
 safety, 158–159
- Disease modifying anti-rheumatic drugs (DMARDs), 147
 azathioprine, 66
 chloroquine, 66
 cyclosporine, 66
 hydroxychloroquine, 66
 leflunomide, 65–66
 methotrexate, 65
 sulfasalazine, 66
- Drug-induced myopathy
 alcoholic myopathy, 270
 colchicine, 270
 corticosteroids, 270
 lipid lowering agents, 270
 statin drugs, 270–271
- Duloxetine, 52
- E**
 Elderly onset rheumatoid arthritis
 aging factors, 147
 characterization, 145
 clinical features
de novo development, 145
 disease duration, 146
 physical examination, 146
 vs. YORA, 146
 differential diagnosis
 ESR and C-reactive protein (CRP), 146
 pro-inflammatory cytokine pattern, 146
 radiographic evaluation, 146
 seropositive patients, 146
 serum rheumatoid factor (RF), 146
 inflammatory arthritis, 145
 symptoms, 145
 treatment, 147–149
- Electrical stimulation, 76
- Enzyme-linked immunosorbent assay (ELISA), 233
- Eosinophilic fasciitis (EF), 279
- Exercise, 110
 aerobic, 109, 125, 126, 128
 characterization, 125
 definition, 125
 degenerative LSS, 104
 and fall prevention, 243–244
 interventions, 98, 107
 muscle strengthening, 126, 128
 nursing home patient, 77
 range-of-motion, 102
 sarcopenia, 261
 stabilization and closed chain, 102
- Eye dryness. *See* Xerophthalmia
- Ezetimibe, 270
- F**
 Facioscapulohumeral dystrophy, 267
 Febuxostat, 210
 Fibrates, 270
 Fibric acid derivatives, 270
 Fibromyalgia syndrome (FMS)
 chronic pain assessment, 46–47
 classification criteria, 45
 clinical presentation, 47
 definition and epidemiology, 45–46
 differential diagnosis, 48, 49
 pain processing and analgesia, 46
 pathogenesis, 46
 physical examination, 47–48
 prevalence, 45
 signs and symptoms, 47
 treatment
 analgesics, 52–53
 anticonvulsants, 52
 antidepressants, 51–52
 comorbid psychiatric disorders, 53
 non-pharmacological management, 53–54
- Fluoxetine, 52
- Fracture healing, 12–13
- Fragility fracture, osteoporosis, 241
- Frailty and Injuries: Cooperative Studies of Intervention Techniques (FICSIT) studies, 126
- G**
 Gadolinium, 279
 GCA. *See* Giant cell arteritis (GCA)
 Geriatric Depression Scale, 88
 Geriatric gout management
 accurate diagnosis, 209
 acute gouty arthritis therapy, 209
 in elderly patients
 drug adherence rates, 210
 health care costs, 211

- Geriatric gout management (*cont.*)
 hyperuricemia treatment
 allopurinol, 210
 febuxostat, 210
 serum urate level, 209–210
- Geriatric rheumatology
 definition, 86
 future aspects, 89–90
- Gerontorheumatology outpatient service (GOS)
 aims and objectives, 87
 assessment, ICF model, 88–89
 follow-up actions, 89
 future aspects, 89–90
 Nijmegen-based GOS, 90
 organization and procedure, 87–88
 patient evaluation, 89
- Giant cell arteritis (GCA)
 diagnosis, 31
 epidemiology, 225
 features, 226
 histology, 227
 imaging, 226–227
 large-vessel, 227–228
 therapy, 31
 treatment, 228
- Glucocorticoids, medium-and small-vessel vasculitis, 203–204
- H**
- Hand osteoarthritis, 175–176
 Health policy, 94–95
 Hematopoietic stem cell (HSC), 6–7
 Henoch-Schönlein purpura, 202
 Hip fracture, 82
 Hip osteoarthritis, 174–175
 HMG-CoA reductase (statins), 262
 Hyaluronic acid viscosupplementation, 67–68
 Hydroxychloroquine (HCQ), 22, 66, 140, 154, 155, 218, 290
 Hyperthyroidism, 269
 Hyperuricemia treatment
 allopurinol, 210
 febuxostat, 210
 serum urate level, 209–210
 Hypothyroidism, 269
- I**
- IA depocorticosteroids, 194
 Immune response therapies
 abatacept, 67
 Anakinra, 67
 anti-TNF alpha agents, 66–67
 rituximab, 67
 Immune system
 B cells, 6
 components, 3
 dendritic cells, 6
 hematopoietic stem cell, 6–7
 inflamm-aging, 7
 thymic involution, 6–7
 T lymphocytes
 apoptosis, 4
 immune replicative senescence, 6
 impaired IL-2 production and proliferation, 5
 memory and naïve human T cells, 4–5
 regulatory T lymphocytes, 5
 T-cell migration, 5
 Th1 and Th2 responses, 5
 Th17 cells, 5
 vaccine efficacy, elder patients, 7
- Immunosenescence, 7
 adaptive immunity
 B-cells, 253–254
 Gavazzi and Krause postulate, 254
 memory T-cells, 253
 T-lymphocytes, 253
 hematopoietic stem cell (HSC), 251
 innate immune system
 alpha-and beta-defensins, 252
 dendritic cells (DC), 252
 Drosophila, 252
 lipopolysaccharide (LPS), 252
 macrophage functions, 252
 natural killer (NK) cells, 252
 phagocytosis, 252–253
 toll-like receptors (TLRs), 252
- Inclusion body myositis (IBM)
 diagnostic criteria, 264, 265
 hereditary inclusion body myopathies (h-IBM), 264
 sporadic inclusion body myositis (s-IBM), 264–265
- Infectious arthritis
 aging, 254
 predisposing risk factors, 254
 therapeutic management, 254
- Inflamm-aging, 7
 Inpatient rehabilitation facilities (IRFs), 80–81
 Interferon-gamma release assays (IGRAs), 39
- J**
- Joints aspiration and injections. *See* Arthrocentesis
- K**
- Kellgren–Lawrence (KL) radiographic grading score, 173
 Knee osteoarthritis, 175–177
- L**
- Langerhans cells (LCs), 6
 Large-vessel giant cell arteritis, 227–228
 Late-onset lupus
 clinical evaluation, 136–140
 differential diagnosis, 138
 disease manifestations, 137–138
 disease prognosis, 140–142
 epidemiology, 135–136
 frequency, 136
 laboratory work-up, 136–140
 serologic findings, 139–140
 syndrome characterization, 138, 139
 treatment, 140
 Late onset mitochondrial myopathy, 267–268
 Late onset muscular dystrophies
 facioscapulohumeral dystrophy, 267
 limb girdle dystrophy, 267
 oculopharyngeal dystrophy, 267
 Late onset scleroderma, 275, 280
 Leflunomide, 65–66
 clinical pharmacology, 155
 efficacy, 156
 safety, 156

Leukocytoclastic vasculitis (LCV), 202
 Limb girdle dystrophy, 267
 Limb length inequality (LLI), 180–181
 Lipid lowering agents, 270
 Local extrinsic risk factors
 occupational demands, 180
 trauma and physical activity, 179–180
 Local intrinsic risk factors
 lower extremity joint alignment, 180
 muscle strength, 180
 Long-term acute care hospitals (LTACs), 79–80
 Louisville reference standards, 233

M

Medium-and small-vessel vasculitis
 ANCA-associated renal vasculitis, 201–202
 antineutrophil cytoplasmic antibodies, 198
 Churg-Strauss syndrome, 200
 epidemiology, 197
 leukocytoclastic vasculitis (LCV), 202
 management in elderly population
 baseline organ function, 203
 cataracts, 204
 comorbid considerations, 203
 glucocorticoids, 203–204
 glucose intolerance and diabetes mellitus, 204
 infection, 203
 myopathy, 204
 osteoporosis, 204
 polypharmacy, 204–205
 microscopic polyangiitis, 200–201
 polyarteritis nodosa, 201
 Wegener's granulomatosis
 characterization, 198
 diagnosis, 199
 elderly, 199
 Metabolic bone diseases. *See* Osteomalacia; Osteoporosis
 Methotrexate, 22, 65, 140
 clinical pharmacology, 156–157
 efficacy, 157
 safety, 157–158
 Microscopic polyangiitis, 200–201
 Milnacipran, 52
 Milwaukee shoulder syndrome, 219
 Mini mental state examination (MMSE), 88
 Modifiable risk factors
 BMD, 179
 crystal arthropathies, 179
 nutrition, 179
 obesity, 179
 Monoclonal gammopathy of undetermined
 significance (MGUS), 279
 Motor unit action potentials (MUAP) assessment, 263
 Mouth dryness. *See* Xerostomia
 Muscle aging, 259
 Muscle disease symptoms, clinical evaluations
 extracellular glutathione depletion, 263
 motor unit action potentials (MUAP)
 assessment, 263
 muscle tenderness, 262
 myopathic weakness, 262
 Muscle strengthening exercise, 126, 128
 Musculoskeletal ultrasound (MSKUS), 216–217
 Mycophenolate mofetil (MMF), 22
 Myofascial pain, 48

Myopathies
 amyloid myopathy, 269–270
 dermatomyositis (DM), 265–267
 drug-induced myopathy
 alcoholic myopathy, 270
 colchicine, 270
 corticosteroids, 270
 lipid lowering agents, 270
 statin drugs, 270–271
 endocrine/metabolic disease
 osteomalacia, 269
 thyroid disease, 268–269
 idiopathic inflammatory myopathies (IIM)
 hereditary inclusion body myopathies (h-IBM), 264
 sporadic inclusion body myositis (s-IBM), 264–265
 late onset mitochondrial myopathy, 267–268
 late onset muscular dystrophies, 267
 medium-and small-vessel vasculitis, 203–204
 paraspinal myopathies, 268
 polymyositis (PM), 265–267
 Myositis. *See specific types*

N

Nephrogenic systemic fibrosis, 279
 Nicotinic acid, 270
 Non-modifiable systemic risk factors
 age, 177
 congenital/developmental conditions, 179
 gender and hormones, 177
 genetic factors, 177
 geographic/racial/ethnicity, 177
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 7–8, 21, 63, 64, 68,
 75–76, 217
 Nursing home patient
 arthritis, 73
 functional assessment
 components, 74
 interdisciplinary care planning meeting, 74
 limitations, 74
 mandated minimal data set, 74
 validated tools, 74
 pain assessment
 cognitive impairment, 75
 monoarticular joint inflammation, 74
 non pharmacological management, 76–77
 osteoarthritis, 74
 pharmacological management, 75–76
 tools, 75
 treatment goals, 75
 Nursing homes, 81–82

O

Oculopharyngeal dystrophy, 267
 Opioid analgesics, 63–65
 Opioid therapy, 76
 Osteoarthritis (OA)
 aerobic exercise, 109
 aging and, 181–182
 calcium pyrophosphate dihydrate (CPPD), 213
 clinical features, 103–104, 109
 diagnosis, 191–192
 epidemiology
 classification, 187
 clinical, 173–174

- Osteoarthritis (OA) (*cont.*)
- criteria for classification, 173
 - demographic characteristics, 187
 - radiographic, 173
 - symptomatic, 173
 - functionally based exercises, 109
 - hand, 175–176
 - hip, 174–175
 - imaging
 - bone scan, radio-labeled bisphosphonates, 191
 - computed tomography (CT), 191
 - MRI, 191
 - osteophyte, 191
 - ultrasonography, 191
 - knee, 175–177
 - patella malalignment and abnormal tracking, 109
 - pathophysiology, 104
 - cartilage structure, 188
 - chondrocytes, 188
 - juxta-articular bone, 189
 - synovium, 189
 - prognosis, 195
 - proprioceptive changes, 109
 - range-of-motion (ROM) exercises and joint mobilization, 109
 - risk factors, 109
 - biomechanic, 180–181
 - local extrinsic, 179–180
 - local intrinsic, 180
 - modifiable, 179
 - non-modifiable systemic, 177–179
 - symptoms and signs
 - joint enlargement characteristics, 189
 - nociceptor pain, 189
 - stiffness, 189
 - therapy
 - acetaminophen, 193
 - capsaicin, 194
 - education and physical measures, 192
 - flavocoxid, 194
 - glucosamine, 194
 - hyaluronic acid, 194
 - IA depocorticosteroids, 194
 - muscle relaxants, 194
 - non-pharmacologic program, 193
 - NSAIDs, 193–194
 - pharmacologic, 193
 - tramadol, 194
 - weight control, 193
- Osteomalacia, 15, 269
- asymptomatic, 246
 - characteristic features, 242
 - 25 dihydroxy-vitamin D level, 246
 - treatment, 246
 - vitamin D deficiency, 245–246
- Osteoporosis
- definition, 241
 - diagnosis
 - absolute fracture risk model (FRAX), 242
 - BMD measurements, 242
 - fracture risk factor assessment, 242
 - exercise, 243–244
 - fall prevention strategy, 244
 - fragility fracture, 241
 - impact
 - hip fractures, 241
 - vertebral fractures, 241
 - males, 242
 - medical costs, 105–106
 - medium-and small-vessel vasculitis, 204
 - morbidity and mortality, elderly, 12
 - nutrition, 243
 - pathophysiology, 13–14
 - physical examination findings and interventions
 - bone mineral density, 106
 - goals, 106
 - high and low impact aerobic exercise, 106
 - postmenopausal women, 106, 107
 - postural re-education, 106
 - senile osteoporosis, 11–12
 - therapeutic options
 - bisphosphonates, 244
 - calcitonin, 245
 - raloxifene, 244
 - teriperatide, 245
- Oxalate crystal deposition disease, 221
- P**
- Paget's disease of bone
- characterization, 246
 - prevalence, 246
 - treatment, 247
- Palmar fasciitis, 279
- Paraproteinemia, 279
- Paraspinal myopathies, 268
- Pharmacotherapy considerations
- antirheumatic medication selection
 - acetaminophen, 62
 - corticosteroids, 65
 - DMARD therapies, 65–66
 - hyaluronic acid viscosupplementation, 67–68
 - NSAIDs, 63, 64
 - nutritional supplements, 67
 - opioid analgesics, 63–65
 - economic and health-care system, 68–69
 - pharmacodynamics, 61–62
 - pharmacokinetic changes
 - drug absorption, 60
 - drug distribution, 61
 - elimination, 61
 - metabolism, 61
 - risks and special concerns, 69
 - topical analgesics, 68
- Physical activity, older adults with arthritis
- aerobic exercise, 125
 - challenges and opportunities, 129
 - characterization, 125
 - definition, 125
 - detriments of inactivity
 - frailty, 127
 - immobility, 127
 - immobilizing leg muscles, 127
 - epidemiology, 126–127
 - health benefits
 - FICSIT studies, 126
 - muscle strengthening, 126
 - muscle contraction, 125
 - pattern, 125
 - physician advice/support, 129
 - physiologic benefits, 127–128
 - range of motion, 125
 - recommendations, 128–129

- social physique anxiety, 129
 - weight bearing, 125
 - Pilocarpine, 290
 - PMR. *See* Polymyalgia rheumatica (PMR)
 - POEMS syndrome, 279
 - Polyarteritis nodosa (PAN), 201
 - diagnosis, 31
 - therapy, 31
 - Polymyalgia rheumatica (PMR)
 - case features, 225
 - classification criteria, 225
 - diagnosis, 101
 - differential diagnosis, 226
 - epidemiology, 225
 - histology, 227
 - imaging, 226–227
 - physical therapy interventions
 - bone and muscle strength maintenance, 102
 - pathophysiology, 103
 - physical examination findings, 101–102
 - recommendations, 103
 - signs and symptoms, 102
 - treatment, 228
 - Polymyositis (PM)
 - autoantibodies, 265, 266
 - diagnosis, 265
 - incidence rates, 265
 - malignancy, 266–267
 - Post acute care
 - home health care, 82
 - inpatient rehabilitation facilities
 - musculoskeletal conditions, 80–81
 - patient characteristics, 80
 - prospective payment system, 80
 - long-term acute care hospitals, 79–80
 - rehabilitation, 82–83
 - skilled nursing facilities, 81–82
 - Primary antiphospholipid syndrome (PAPS), 231
 - Progressive interstitial lung disease (ILD), 282
 - Propoxyphene, 76
 - Proprioception, 181
 - Prospective payment system (PPS), 80
 - Pseudogout
 - acute, 216
 - characterization, 214
 - chronic, 214
 - CPPD, 213
 - familial forms, 214
 - Psoriasis and Psoriatic arthritis, 20
 - Public health, 93–94
 - Pulmonary arterial hypertension (PAH), 280–282
- Q**
- Quantiferon-TB Gold In Tube (QFT-IT) test, 39
- R**
- Raloxifene, 244
 - Raynaud's phenomenon
 - abnormal nailfold capillary microscopy, 277
 - age of onset, 276
 - connective tissue disease (CTD), 276–277
 - diagnosis, 277–278
 - differential diagnosis, 276, 277
 - distinguishing feature, 276
 - pharmacologic agents, 278
 - Regulatory T cells (Tregs), 3, 5
 - Rheumatoid arthritis (RA), 33
 - aging, 7
 - aquatic exercise, 108
 - clinical features and physical therapy intervention, 103, 108
 - epidemiology, 35–36
 - history, 39
 - latent tuberculosis infection
 - biologic therapy, elderly RA patients, 41
 - detection, 39–40
 - diagnosis, 39
 - screening, guidelines, 41
 - TST vs. QFT-IT, 40–41
 - neuropsychiatric manifestations, 28
 - non-or low-impact aerobic exercises, 108
 - patient education, 108
 - physical examination findings, 106
 - range-of-motion exercises and isometric exercises, 108
 - resistive exercises, 108
 - resting and dynamic splints, 108
 - Rituximab, 67, 290
- S**
- Sarcopenia
 - behavioral alteration, 260
 - bone and muscle strength, descriptors for, 261
 - definition, 259
 - disuse deconditioning, 260
 - impaired strength, 259
 - muscle aging, 259
 - muscular alterations, 260
 - neuromuscular factors, 260
 - treatment
 - exercise, 261
 - protein intake, 262
 - strength training, 261
 - therapies, 262
 - Scleroderma
 - age at disease onset, impact of
 - mortality, 280
 - pulmonary arterial hypertension (PAH), 280
 - aging scleroderma patient
 - heart diseases, 281
 - PAH, 281
 - skin telangiectasias, 281
 - skin thickening, 280
 - classification and demographics, 276
 - clinical features
 - Raynaud's phenomenon, 276–278
 - systemic disease, 278
 - eosinophilic fasciitis (EF), 279
 - gadolinium, 279
 - management
 - geriatric treatment principles, 283
 - organ specific therapies, 282
 - PAH, 282
 - progressive interstitial lung disease (ILD), 282
 - skin, 282–283
 - treatment principles, 281–282
 - monoclonal gammopathy of undetermined significance (MGUS), 279
 - nephrogenic systemic fibrosis, 279
 - palmar fasciitis, 279
 - paraproteinemia, 279

- Scleroderma (*cont.*)
 POEMS syndrome, 279
 scleromyxedema, 279
- Scleromyxedema, 279
- Secondary antiphospholipid syndrome (SAPS), 231
- Selective estrogen receptor modulator (SERM), 244
- Selective serotonin reuptake inhibitors (SSRIs), 52
- Senile osteoporosis, 11–12
- Septic arthritis, 10
- Short questionnaire to assess health-enhancing physical activity (SQUASH), 89
- Sjögren's syndrome (SS)
 chronic inflammatory process, 29
 clinical features
 cancer, 289
 esophagus dryness, 288
 exocrine glands destruction, 288
 extraepithelial diseases, 288–289
 immunological changes, 289
 lymphoma complications, 289
 periepithelial diseases, 288
 sicca symptoms, 288
 thyroid disease, 289
 vaginal dryness, 288
 clinical manifestation, 29
 definition, 287
 diagnosis, 30
 epidemiology, 287–288
 neurologic involvement, 29
 pathophysiologic mechanism, 30
 prevalence, 29
 primary Sjögren's syndrome, 287, 288
 secondary Sjögren's syndrome, 287, 289, 290
 therapy, 30
 treatment, in geriatric patient
 systemic manifestations, 290
 xerophthalmia, 289–290
 xerostomia, 290
- Skilled nursing facility (SNF), 81–82
- Social physique anxiety, 129
- Sporadic inclusion body myositis (s-IBM)
 diagnosis, 264
 standard medical therapy, 264
- Statin-induced myopathy, 270
- Statins, 21–22
- Sulfasalazine, 66
 clinical pharmacology, 158
 efficacy, 158
 safety, 158–159
- Systemic lupus erythematosus (SLE), 231
 autoantibodies, 28
 brain MRI, abnormalities, 28
 classification, 136
 diagnosis, 28, 136
 disease activity, 141
 late-onset lupus (*see* Late-onset lupus)
 organ function decline, 28
 pharmacological interventions, 140
 prevalence, 28
 survival, 142
 therapy, 29
 treatment, 140
- Systemic sclerosis, 21, 278
- Systemic vasculitis, 30
- T**
- Temporal arteritis. *See* Giant cell arteritis (GCA)
- Teriperatide, 245
- Thermal therapy, 76
- Thymic involution, 6–7
- Thyroid disease
 hyperthyroidism, 269
 hypothyroidism, 268–269
- T lymphocytes
 apoptosis, 4
 immune replicative senescence, 6
 impaired IL–2 production and proliferation, 5
 memory and naïve human T cells, 4–5
 regulatory T lymphocytes, 5
 T-cell migration, 5
 Th1 and Th2 responses, 5
 Th17 cells, 5
- Tricyclic antidepressants (TCAs), 51–52
- Tuberculosis, RA
 biologic therapy, elderly patients
 recommendations, 41
 risk during, 37–38
 risk prior to, 37
 clinical and radiological characteristics, 38
 epidemiology, 35–36
 history, 35
- U**
- Ultrasound guided arthrocentesis
 advantages, 122
 indirect technique, 122
 real time technique, 123
- V**
- Varicella-zoster virus (VZV), 5
- Venlafaxine, 52
- Visual analogue scales (VAS), 88
- W**
- Wegener's granulomatosis
 characterization, 198
 diagnosis, 199
 in elderly
 vs. general patients, clinical characteristics, 199
 survival curves, patients, 200
- Widespread pain
 fibromyalgia syndrome (*see* Fibromyalgia syndrome (FMS))
 pathogenesis, 46
 psychiatric conditions, 48
- X**
- Xanthine oxidase (XO) inhibitor, 210
- Xerophthalmia, 289–290
- Xerostomia, 290